Compare Abbott Laboratories (ABT) vs Taskus Inc (TASK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Taskus Inc — how do they compare? Abbott Laboratories trades at $95.41 (market cap $166.94B), while Taskus Inc trades at $5.12 (market cap $475.98M). The key difference: Abbott Laboratories is far larger — about 350.7× Taskus Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Taskus Inc pays none. Which is the better fit depends on your goals.
| ABT | TASK | |
|---|---|---|
Market Cap | $166.94B | $475.98M |
Sector | Health | Technology |
52-Week High | $136.62 | $18.21 |
52-Week Low | $82.57 | $4.57 |
Enterprise Value | $193.69B | $871.68M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
TaskUs trades at $5.19, up 3.18% today, with a bearish technical signal despite strong fundamentals including a P/E of 4.59 and net income margin of 8.7%. Recent Q1 2026 earnings missed expectations, but revenue reached $1.18B in 2025. The company appointed a new CFO in June 2026 and reported growing interest in robotaxi services, indicating strategic positioning in digital customer experience.
The stock appears undervalued with a consensus price target of $9.50, offering significant upside potential. Risks include recent earnings volatility and competitive pressures in outsourcing services. Analyst sentiment is mixed with 55% buy ratings, suggesting cautious optimism amid near-term execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
